Imprimis Pharmaceuticals looks to expand its Ophthalmology Portfolio with LessDrops™
Thursday, January 08, 2015
Imprimis Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, today announced its plans to introduce proprietary triamcinolone acetonide and moxifloxacin hydrochloride (Tri-Moxi) and prednisolone acetate and moxifloxacin hydrochloride (Pred-Moxi) combination eye drop formulations for patients following laser refractive surgery, including LASIK and photorefractive keratectomy (PRK) surgery, cataract and other ocular surgeries.
The current treatment regimens following LASIK, cataract and other ocular surgeries include two or more daily self-administered topical eye drops for up to 4 weeks. It is well documented that current eye drop regimens can be confusing to patients, creating non-compliance issues and incorrect dosing.1 For some high volume ocular surgeries, like PRK and LASIK, the company estimates that its combination Tri-Moxi and Pred-Moxi topical eye drop formulations can require up to 50% fewer drops to be administered by patients and may cost up to 75% less than current post-surgery drops regimens. Importantly, Imprimis' topical compounded drops may be eligible for reimbursement to patients covered by both public and private insurance plans. A prospective evaluation of de-identified quality assurance data of the Tri-Moxi and Pred-Moxi topical formulations for patients following LASIK surgery enrolled in the fall of 2014 at the Cleveland Eye Clinic. Imprimis expects the results of this research to be announced by the end of January 2015.
Imprimis' ophthalmic compound formulations have been optimized for the isotonicity and pH most compatible with the eye. Imprimis' patent-pending drug formulations allow for increased solubility of active pharmaceutical ingredients, creating small, uniform particle sizes which enable functionality such as an injectable or use as a topical eye drop.
"We are pleased to make our Tri-Moxi and Pred-Moxi formulations available soon – as an eye drop. This is a new application of our proprietary compound drug formulations, which allows for the combination of active pharmaceutical ingredients that do not normally combine well for administration. To date, we have made this technology available in single-use injectable ophthalmic formulations, which numerous ophthalmologists have reported on at major clinical meetings. While 95% of leading ophthalmologists surveyed would prefer Dropless Therapy2, many in the U.S. and abroad continue to prescribe eye drops for their patients following cataract surgery and other ocular procedures. The current single-API steroid and antibiotic eye drop choices for physicians and patients create compliance and cost issues for each of the parties involved. As a result, and in an effort to build a bridge to a 'Dropless' future for procedures like cataract surgery and to address the need for LessDrops™ in procedures like LASIK, we are seizing upon the opportunity to dramatically reduce the number of eye drop applications and lower costs by using our compounded formulations," stated Imprimis CEO Mark L. Baum.
Baum concluded, "Imprimis believes in and is committed to quality, accessible innovation and solving unmet needs in the markets it serves. In 2015 and beyond, we look forward to continuing to introduce new applications of our proprietary formulations and technologies, particularly in ophthalmology, for injectable and topical applications."
Source : http://imprimispharma.investorroom.com/
